Implications of the allosteric kinetics of cytochrome P450s

Drug Discovery Today

Volumn 9, Issue 11, 2004, Pages 478-484

  Atkins, William M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

ALLOSTERISM; BIOPHYSICS; CATALYSIS; COMPLEX FORMATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYMOLOGY; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; PREDICTION; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY;

EID: 2442626615     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03072-7     Document Type: Review

References (51)

1. Shou M. Kinetic analysis for multiple substrate interaction at the active site of cytochrome P450. Methods Enzymol. 357:2002;261-276
2. Shou M., et al. Enzyme kinetics of cytochrome P450-mediated reactions. Curr. Drug Metab. 2:2001;17-36
3. Houston J.B., Kenworthy K.E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 28:2000;246-254
4. Kenworthy K.E., et al. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 29:2001;1644-1651
5. Hlavica P., Lewis D.F. Allosteric phenomena in cytochrome P450-catalyzed monooxygenations. Eur. J. Biochem. 268:2001;4817-4832
6. Tracy T.S. Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr. Drug Metab. 4:2003;341-346
7. Korzekwa K.R., et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry. 37:1998;4137-4147
8. Tang W., Stearns R.A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr. Drug Metab. 2:2001;185-198
9. Ngui J.S., et al. In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metab. Dispos. 29:2001;877-886
10. Atkins W.M., et al. Is there a toxicological advantage for non-hyperbolic kinetics in cytochrome P450 catalysis? Functional allostery from 'distributive catalysis'. J. Biol. Chem. 277:2002;33258-33266
11. Cook D.L., Atkins W.M. Enhanced detoxication due to distributive catalysis and toxic thresholds: a kinetic analysis. Biochemistry. 36:1997;10801-10806
12. Gorski J.C., et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47:1994;1643-1653
13. Khan K.K., et al. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol. Pharmacol. 61:2002;495-506
14. Hutzler J.M., et al. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. 29:2001;1029-1034
15. Hutzler J.M., et al. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch. Biochem. Biophys. 410:2003;16-24
16. Wang R.W., et al. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28:2000;360-366
17. Galetin A., et al. Multisite kinetic analysis of interactions between prototypical CYP3A4 substrates: midazolam, testosterone, and nifedipine. Drug Metab. Dispos. 31:2003;1108-1116
18. He Y.A., et al. Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch. Biochem. Biophys. 409:2003;92-101
19. Hosea N.A., et al. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry. 39:2000;5929-5939
20. Galetin A., et al. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab. Dispos. 30:2002;1512-1522
21. Tracy T.S., et al. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab. Dispos. 30:2002;385-390
22. Ekins S., et al. Autoactivation and activation of the cytochrome P450s. Int. J. Clin. Pharmacol. Ther. 36:1998;642-651
23. Ekins S., et al. Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. 286:1998;1253-1259
24. Egnell A.C., et al. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J. Pharmacol. Exp. Ther. 305:2003;1251-1262
25. Hutzler J.M., et al. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur. J. Pharm. Sci. 14:2001;47-57
26. Tang W., et al. Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J. Pharmacol. Exp. Ther. 291:1999;1068-1074
27. Domanski T.L., et al. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry. 40:2001;10150-10160
28. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39:1999;1-17
29. 2+. Drug Metab. Dispos. 28:2000;1198-1201
30. Hutzler J.M., et al. Effect of carbonate anion on cytochrome P450 2D6-mediated metabolism in vitro: the potential role of multiple oxygenating species. Arch. Biochem. Biophys. 417:2003;165-175
31. Shou M., et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry. 33:1994;6450-6455
32. Cupp-Vickery J., et al. Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3050-3055
33. 1H NMR study. J. Am. Chem. Soc. 116:1994;4866-4873
34. Rock D.A., et al. A method for determining two substrates binding in the same active site of cytochrome P450BM3: an explanation of high energy omega product formation. Arch. Biochem. Biophys. 416:2003;9-16
35. Dabrowski M.J., et al. Pyrene-pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate-binding site. J. Am. Chem. Soc. 124:2000;11866-11867
36. Scott E.E., et al. An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. Proc. Natl. Acad. Sci. U. S. A. 100:2003;13196-13201
37. Williams P.A., et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 424:2003;464-468
38. Wester M.R., et al. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: evidence for multiple substrate binding modes. Biochemistry. 42:2003;6370-6379
39. Schoch G.A., et al. Structure of human microsomal cytochrome P450 2C8: evidence for a peripheral fatty acid binding site. J. Biol. Chem. 279:2003;9497-9503
40. Harlow G.R., Halpert J.R. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc. Natl. Acad. Sci. U. S. A. 95:1998;6636-6641
41. Schrag M.L., Wienkers L.C. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch. Biochem. Biophys. 391:2001;49-55
42. Egnell A.C., et al. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J. Pharmacol. Exp. Ther. 307:2003;878-887
43. Torimoto N., et al. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry. 42:2003;15068-15077
44. Stone A.N., et al. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos. 31:2003;1086-1089
45. Tsoutsikos P., et al. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem. Pharmacol. 67:2004;191-199
46. Fisher M.B., et al. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab. Dispos. 28:2000;560-566
47. Iyer L.V., et al. Glucuronidation of 1′-hydroxyestragole (1′-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. Toxicol. Sci. 73:2003;36-43
48. Gamage N.U., et al. Structure of a human carcinogen-converting enzyme, SULT1A1. Structural and kinetic implications of substrate inhibition. J. Biol. Chem. 278:2003;7655-7662
49. Tabrett C.A., Coughtrie M.W. Phenol sulfotransferase 1A1 activity in human liver: kinetic properties, interindividual variation and re-evaluation of the suitability of 4-nitrophenol as a probe substrate. Biochem. Pharmacol. 66:2003;2089-2097
50. Martin C., et al. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58:2000;624-632
51. Yu E.W., et al. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science. 300:2003;976-980